JP2018536002A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536002A5
JP2018536002A5 JP2018528691A JP2018528691A JP2018536002A5 JP 2018536002 A5 JP2018536002 A5 JP 2018536002A5 JP 2018528691 A JP2018528691 A JP 2018528691A JP 2018528691 A JP2018528691 A JP 2018528691A JP 2018536002 A5 JP2018536002 A5 JP 2018536002A5
Authority
JP
Japan
Prior art keywords
vaccine composition
domain
mic
fusion protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018528691A
Other languages
English (en)
Japanese (ja)
Other versions
JP7099956B2 (ja
JP2018536002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/064969 external-priority patent/WO2017096374A1/en
Publication of JP2018536002A publication Critical patent/JP2018536002A/ja
Publication of JP2018536002A5 publication Critical patent/JP2018536002A5/ja
Priority to JP2022105405A priority Critical patent/JP7564842B2/ja
Application granted granted Critical
Publication of JP7099956B2 publication Critical patent/JP7099956B2/ja
Priority to JP2024167997A priority patent/JP2024177207A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018528691A 2015-12-04 2016-12-05 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種 Active JP7099956B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022105405A JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US62/263,377 2015-12-04
US201662422454P 2016-11-15 2016-11-15
US62/422,454 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105405A Division JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Publications (3)

Publication Number Publication Date
JP2018536002A JP2018536002A (ja) 2018-12-06
JP2018536002A5 true JP2018536002A5 (https=) 2020-01-16
JP7099956B2 JP7099956B2 (ja) 2022-07-12

Family

ID=57590885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018528691A Active JP7099956B2 (ja) 2015-12-04 2016-12-05 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2022105405A Active JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A Pending JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022105405A Active JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A Pending JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Country Status (24)

Country Link
US (3) US10993971B2 (https=)
EP (1) EP3383426A1 (https=)
JP (3) JP7099956B2 (https=)
KR (1) KR20180088458A (https=)
CN (1) CN108770343A (https=)
AU (3) AU2016362597C1 (https=)
BR (1) BR112018010705A8 (https=)
CA (1) CA3005910A1 (https=)
CL (3) CL2018001470A1 (https=)
CO (1) CO2018006642A2 (https=)
CR (2) CR20180350A (https=)
CU (2) CU24609B1 (https=)
EA (1) EA201891287A1 (https=)
IL (1) IL259490A (https=)
MX (2) MX2018006785A (https=)
MY (1) MY199248A (https=)
NZ (1) NZ742663A (https=)
PE (2) PE20230495A1 (https=)
PH (1) PH12018501170A1 (https=)
RU (2) RU2747296C2 (https=)
SG (1) SG11201804597TA (https=)
TN (1) TN2018000187A1 (https=)
WO (1) WO2017096374A1 (https=)
ZA (1) ZA202204223B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
BR112020019938A2 (pt) 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
CA3095174A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
US20240207385A1 (en) * 2020-02-26 2024-06-27 The Wistar Institute Of Anatomy And Biology Compositions comprising self-assembling vaccines and methods of using the same
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
CN121620389A (zh) * 2023-04-28 2026-03-06 先为(海南)生物科技有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0643559B1 (en) 1992-05-06 1999-04-14 The President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003028632A2 (en) 2001-10-01 2003-04-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of a preventive vaccine for filovirus infection in primates
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
EP1504037B1 (en) 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2665090A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
WO2011046842A1 (en) 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US8889044B2 (en) 2009-12-18 2014-11-18 Kao Corporation Method for producing mesoporous silica particles
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
EP2758072A1 (en) * 2011-09-23 2014-07-30 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
ES2925654T3 (es) 2011-09-30 2022-10-19 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
EP2812027A1 (en) * 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
JP6518199B6 (ja) * 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
KR20150130462A (ko) 2013-03-15 2015-11-23 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
WO2015139020A2 (en) * 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers

Similar Documents

Publication Publication Date Title
JP2018536002A5 (https=)
ES2848064T3 (es) Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака
JP2020528911A5 (https=)
Fifis et al. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
JP2021531345A5 (https=)
JP2019526580A5 (https=)
JP2006020648A5 (https=)
JP2016128513A5 (https=)
JP2019511222A5 (https=)
PE20181490A1 (es) Tratamientos contra el cancer de utero
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
JP2016516723A5 (https=)
JP2012501959A5 (https=)
JP2016539946A5 (https=)
JP2008530245A5 (https=)
JP2015506179A5 (https=)
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
JP2018509163A5 (https=)
JP2019531293A5 (https=)
JP2012517799A5 (https=)
JP2022130623A5 (https=)
JP2014502961A5 (https=)
JP2012021028A5 (https=)